“compound 6g” is an oral inhibitor of the sodium-glucose co-transporters (SGLTs) 1 and 2, intended for the treatment of hyperglycemia. SGLT2 selective inhibitors (gliflozins) are approved for treatment of type 2 diabetes, and an SGLT1/2 dual inhibitor is expected to result in greater glycemic control. Like other SGLT inhibitors, this molecule [...]
< 1 minute read
Sep. 18, 2021
Compound 6g: An Oral Inhibitor of the Sodium-Glucose Co-Transporters 1 and 2
"compound 6g"
potent and orally available SGLT1/2 dual inh. activity in diabetes glucose tolerance model based on natural product phlorizin Bioorg. Med. Chem. Lett., Jul. 5, 2020 Janssen R&D, Spring House, PA.